Meet Jimini: clinician-supervised AI infrastructure for mental health

Text Link

No items found.

investment updates

TLDR

• Developed by leaders in psychology, AI, and biotech, Jimini Health is the first patient-facing mental health AI platform built to keep clinicians in the loop across the full course of care
• Jimini's Sage is a behavioral health AI care team member that works with patients and clinicians.
• The company created its own clinic to ensure safety and effectiveness while also taking a regulatory-minded approach.

Why we invested

Jimini Health sits at the intersection of a massive unmet need in behavioral health and a moment of rapid adoption of AI across our healthcare system.

Clinicians, patients and administrators are actively seeking AI tools that can help manage overwhelming demand, improve outcomes and reduce burnout. Behavioral health faces well documented workforce shortages and rising patient complexity. The need is structural.

A second-time founder, Jimini Health CEO and co-founder Luis Voloch previously co-founded Immunai, a billion dollar AI company that built an immune cell "atlas" using AI to advance cancer immunotherapy. Luis' founding team includes Mark Jacobstein and Chiara Waingarten, both who worked with Luis for years at Immunai, and Sahil Sud.

"Luis took on one of the hardest problems at Immunai," M13 partner Morgan Blumberg said. "With Jimini, he's applying that ambition to an equally large but underdeveloped market. The team brings scientific rigor and a practical understanding of care delivery, working alongside clinicians with a high bar for safety and credibility."

Blumberg was excited by Jimini's ambition to push the frontier of medicine in mental health using AI as the core infrastructure for care delivery.

Timing matters. Some of those tailwinds include regulatory momentum. The Centers for Medicare and Medicaid Services and the US Food and Drug Administration are increasingly opening up to AI-enabled care models, creating pathways for reimbursement and approval that didn't exist before.

When clinical need, regulatory openness and technical capability align, adoption can move quickly. Jimini is positioned at that inflection point.

Clinician and AI collaboration central to Jimini's model

Jimini's Sage is an AI behavioral health care team member that works with clinicians to support patients through language-driven interactions that extend care beyond weekly sessions.

"Sage provides a day-to-day high touch level of support that was never possible before," Voloch said.

Behavioral health is uniquely suited for this approach. Sage is not a standalone chatbot but a tightly integrated part of the care team that works under clinical oversight to help deliver better outcomes and higher-quality care.

The goal is to enhance quality and continuity of care while preserving accountability and safety. In behavioral health, language is both the primary diagnostic tool and the core therapeutic instrument, making it uniquely suited to LLMs, which excel at understanding and generating nuanced text.

Jimini took the unusual step of building and operating its own clinic. Full-time clinicians treat real patients using Sage, allowing them to iterate quickly without sacrificing safety, Voloch said.

Jimini does not use patient data for training models. Instead, every product decision is informed by real-world clinician feedback, and every model update can be evaluated against real world outcomes and risk metrics, not just synthetic benchmarks.

"This is the only way that we know how to develop products safely and quickly, and we can have full oversight and constant feedback to improve from clinicians," Voloch said.

Creating a strategy for safe AI in mental health

Mental health-related purposes are the primary use cases for tools like ChatGPT. OpenAI reported in October 2025 that more than 1 million ChatGPT users reference suicidal ideations each week.

"People are using generative AI for mental health support whether any of us like it or not," Voloch said.

So the question is whether it will be deployed inside a clinically governed system - or outside of one. Sage engages patients everyday, between sessions, in a way most time-constrained human clinicians simply can't do. By maintaining a continuous line of communication, it can help reinforce therapeutic techniques, identify insights and keep patients more engaged in their care journey, Voloch said.

Clinicians, in turn, gain a more complete and timely picture of each patient, which can inform better decisions during limited face-to-face time. They have visibility into what Sage does and the ability to steer and oversee Sage's work.

This co-pilot model ensures that AI-initiated interactions don't happen in a vacuum: they're grounded in a therapeutic plan and supervised by licensed professionals who understand each patient's broader context, which is essential for treating more complex, higher acuity patients.

"We make it very clear [to patients] that their data is safe, secure and that the clinician has oversight on what the AI is doing so they can feel at ease, clinically, about what's happening," Voloch said. "And we put clinicians at ease by showing them that this is built for clinical use. 'You have full visibility, your patient's data is secure, and it's an AI that is actually made for this, unlike consumer products.'"

The origin story: Why Jimini exists

Voloch started the company in 2023 with Jacobstein, another repeat entrepreneur and former executive at Guardant Health; Waingarten, a former Immunai colleague; and Sud, who previously worked at Palantir and Ribbon. The broader c-suite includes seasoned executives Lynn Hamilton (previously Talkspace CCO), Dr Bill Hudenko (Academic Psychologist at Dartmouth and leader in digital method for treating SMI), and Chief Scientist and Stanford Professor Johannes Eichstaedt.

"We felt the right path forward was a fully personalized superhuman AI care team member that works in concert with human clinicians and can see way more data than an individual human clinician could do on their own," Voloch said.

Voloch left his MIT AI Ph.D. program, where he won the program's best thesis award among all Ph.D students for his Master of Science degree in a subfield of AI's reinforcement learning called multiarmed bandits. He joined Palantir's core AI team building the company's foundational models. He later co-founded Immunai, an AI-driven cancer drug development company now valued at more than $1 billion, and was briefly faculty as Stanford's GSB before starting Jimini Health.

Over the past 15 years, digital health companies have meaningfully expanded access. Telehealth is mainstream, and insurance reimbursement for therapy and psychiatry is more common than it was pre-2020.

"This past generation of companies largely improved the access problem," Voloch said. "You can get telehealth easily. You can get therapy reimbursed by insurance more easily. You can find the right clinician more easily."

For Jimini, he and his founders saw an opportunity to build from a different perspective: not just on expanding access to existing care models, but building a company with science and AI innovation at its core, to create new and better care models.

Taking Jimini into the future

Voloch and his team want to partner with several of the largest behavioral health provider organizations in the country. They also will spearhead major expansions in the Sage product in terms of clinical scenarios, acuity, level and modalities with which it engages with patients.

"The next generation of companies is reinventing care," Voloch said. "To radically improve it, Jimini is pioneering novel therapeutic interactions and diagnostic methods that never existed before."

The company is also taking steps toward government approvals and working with government officials to be like the standard or even create the standard of behavioral care.

"The market is ready for that," Blumberg said. "This is a very hard problem that affects everyone. And this is the right solution, at the right time, with the right team."

What this means for founders, technologists, investors

• Jimini is not just another mental health app - it is an attempt to build clinical-grade AI infrastructure for behavioral health that works alongside, and doesn't replace clinicians.
• The company offers both meaningful clinical impact and significant upside for investors backing the next generation of AI-native health care companies.
• The new funding from M13 will go primarily toward advancing the product and partnering with some of the largest behavioral health provider organizations in the U.S., with the goal of expanding Sage across more clinical settings, acuity levels and modalities.

Read more about Jimini

AI and the future of therapy with Luis Voloch of Jimini Health

Interview With Luis F Voloch Co-founder and CEO of Jimini Health

Jimini Health Launches with $8M in Funding to Transform Mental Health with Responsible AI-Supported Therapy

Follow Jimini

Learn more at jiminihealth.com or jiminihealth.com/blog.

Find out how Jimini can work for your organization: https://jiminihealth.typeform.com/to/hnRUXTjO

Follow the company on LinkedIn at https://www.linkedin.com/company/jiminihealth/.

Follow Luis Voloch at https://www.linkedin.com/in/luisvoloch/.

TLDR

• Developed by leaders in psychology, AI, and biotech, Jimini Health is the first patient-facing mental health AI platform built to keep clinicians in the loop across the full course of care
• Jimini's Sage is a behavioral health AI care team member that works with patients and clinicians.
• The company created its own clinic to ensure safety and effectiveness while also taking a regulatory-minded approach.

Why we invested

Jimini Health sits at the intersection of a massive unmet need in behavioral health and a moment of rapid adoption of AI across our healthcare system.

Clinicians, patients and administrators are actively seeking AI tools that can help manage overwhelming demand, improve outcomes and reduce burnout. Behavioral health faces well documented workforce shortages and rising patient complexity. The need is structural.

A second-time founder, Jimini Health CEO and co-founder Luis Voloch previously co-founded Immunai, a billion dollar AI company that built an immune cell "atlas" using AI to advance cancer immunotherapy. Luis' founding team includes Mark Jacobstein and Chiara Waingarten, both who worked with Luis for years at Immunai, and Sahil Sud.

"Luis took on one of the hardest problems at Immunai," M13 partner Morgan Blumberg said. "With Jimini, he's applying that ambition to an equally large but underdeveloped market. The team brings scientific rigor and a practical understanding of care delivery, working alongside clinicians with a high bar for safety and credibility."

Blumberg was excited by Jimini's ambition to push the frontier of medicine in mental health using AI as the core infrastructure for care delivery.

Timing matters. Some of those tailwinds include regulatory momentum. The Centers for Medicare and Medicaid Services and the US Food and Drug Administration are increasingly opening up to AI-enabled care models, creating pathways for reimbursement and approval that didn't exist before.

When clinical need, regulatory openness and technical capability align, adoption can move quickly. Jimini is positioned at that inflection point.

Clinician and AI collaboration central to Jimini's model

Jimini's Sage is an AI behavioral health care team member that works with clinicians to support patients through language-driven interactions that extend care beyond weekly sessions.

"Sage provides a day-to-day high touch level of support that was never possible before," Voloch said.

Behavioral health is uniquely suited for this approach. Sage is not a standalone chatbot but a tightly integrated part of the care team that works under clinical oversight to help deliver better outcomes and higher-quality care.

The goal is to enhance quality and continuity of care while preserving accountability and safety. In behavioral health, language is both the primary diagnostic tool and the core therapeutic instrument, making it uniquely suited to LLMs, which excel at understanding and generating nuanced text.

Jimini took the unusual step of building and operating its own clinic. Full-time clinicians treat real patients using Sage, allowing them to iterate quickly without sacrificing safety, Voloch said.

Jimini does not use patient data for training models. Instead, every product decision is informed by real-world clinician feedback, and every model update can be evaluated against real world outcomes and risk metrics, not just synthetic benchmarks.

"This is the only way that we know how to develop products safely and quickly, and we can have full oversight and constant feedback to improve from clinicians," Voloch said.

Creating a strategy for safe AI in mental health

Mental health-related purposes are the primary use cases for tools like ChatGPT. OpenAI reported in October 2025 that more than 1 million ChatGPT users reference suicidal ideations each week.

"People are using generative AI for mental health support whether any of us like it or not," Voloch said.

So the question is whether it will be deployed inside a clinically governed system - or outside of one. Sage engages patients everyday, between sessions, in a way most time-constrained human clinicians simply can't do. By maintaining a continuous line of communication, it can help reinforce therapeutic techniques, identify insights and keep patients more engaged in their care journey, Voloch said.

Clinicians, in turn, gain a more complete and timely picture of each patient, which can inform better decisions during limited face-to-face time. They have visibility into what Sage does and the ability to steer and oversee Sage's work.

This co-pilot model ensures that AI-initiated interactions don't happen in a vacuum: they're grounded in a therapeutic plan and supervised by licensed professionals who understand each patient's broader context, which is essential for treating more complex, higher acuity patients.

"We make it very clear [to patients] that their data is safe, secure and that the clinician has oversight on what the AI is doing so they can feel at ease, clinically, about what's happening," Voloch said. "And we put clinicians at ease by showing them that this is built for clinical use. 'You have full visibility, your patient's data is secure, and it's an AI that is actually made for this, unlike consumer products.'"

The origin story: Why Jimini exists

Voloch started the company in 2023 with Jacobstein, another repeat entrepreneur and former executive at Guardant Health; Waingarten, a former Immunai colleague; and Sud, who previously worked at Palantir and Ribbon. The broader c-suite includes seasoned executives Lynn Hamilton (previously Talkspace CCO), Dr Bill Hudenko (Academic Psychologist at Dartmouth and leader in digital method for treating SMI), and Chief Scientist and Stanford Professor Johannes Eichstaedt.

"We felt the right path forward was a fully personalized superhuman AI care team member that works in concert with human clinicians and can see way more data than an individual human clinician could do on their own," Voloch said.

Voloch left his MIT AI Ph.D. program, where he won the program's best thesis award among all Ph.D students for his Master of Science degree in a subfield of AI's reinforcement learning called multiarmed bandits. He joined Palantir's core AI team building the company's foundational models. He later co-founded Immunai, an AI-driven cancer drug development company now valued at more than $1 billion, and was briefly faculty as Stanford's GSB before starting Jimini Health.

Over the past 15 years, digital health companies have meaningfully expanded access. Telehealth is mainstream, and insurance reimbursement for therapy and psychiatry is more common than it was pre-2020.

"This past generation of companies largely improved the access problem," Voloch said. "You can get telehealth easily. You can get therapy reimbursed by insurance more easily. You can find the right clinician more easily."

For Jimini, he and his founders saw an opportunity to build from a different perspective: not just on expanding access to existing care models, but building a company with science and AI innovation at its core, to create new and better care models.

Taking Jimini into the future

Voloch and his team want to partner with several of the largest behavioral health provider organizations in the country. They also will spearhead major expansions in the Sage product in terms of clinical scenarios, acuity, level and modalities with which it engages with patients.

"The next generation of companies is reinventing care," Voloch said. "To radically improve it, Jimini is pioneering novel therapeutic interactions and diagnostic methods that never existed before."

The company is also taking steps toward government approvals and working with government officials to be like the standard or even create the standard of behavioral care.

"The market is ready for that," Blumberg said. "This is a very hard problem that affects everyone. And this is the right solution, at the right time, with the right team."

What this means for founders, technologists, investors

• Jimini is not just another mental health app - it is an attempt to build clinical-grade AI infrastructure for behavioral health that works alongside, and doesn't replace clinicians.
• The company offers both meaningful clinical impact and significant upside for investors backing the next generation of AI-native health care companies.
• The new funding from M13 will go primarily toward advancing the product and partnering with some of the largest behavioral health provider organizations in the U.S., with the goal of expanding Sage across more clinical settings, acuity levels and modalities.

Read more about Jimini

AI and the future of therapy with Luis Voloch of Jimini Health

Interview With Luis F Voloch Co-founder and CEO of Jimini Health

Jimini Health Launches with $8M in Funding to Transform Mental Health with Responsible AI-Supported Therapy

Follow Jimini

Learn more at jiminihealth.com or jiminihealth.com/blog.

Find out how Jimini can work for your organization: https://jiminihealth.typeform.com/to/hnRUXTjO

Follow the company on LinkedIn at https://www.linkedin.com/company/jiminihealth/.

Follow Luis Voloch at https://www.linkedin.com/in/luisvoloch/.

No items found.